Effects of Linezolid on Suppressing In Vivo Production of Staphylococcal Toxins and Improving Survival Outcomes in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia | Zendy

Binh An Diep | Zendy; Anna Afasizheva | Zendy; Hoan N. Le | Zendy; Osamu Kajikawa | Zendy; Gustavo MatuteBello | Zendy; Christine Tkaczyk | Zendy; Bret R. Sellman | Zendy; Cédric Badiou | Zendy; Gérard Lina | Zendy; Henry F. Chambers | Zendy

Open Access

Effects of Linezolid on Suppressing In Vivo Production of Staphylococcal Toxins and Improving Survival Outcomes in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Necrotizing Pneumonia

Author(s) -

Binh An Diep,

Anna Afasizheva,

Hoan N. Le,

Osamu Kajikawa,

Gustavo MatuteBello,

Christine Tkaczyk,

Bret R. Sellman,

Cédric Badiou,

Gérard Lina,

Henry F. Chambers

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit129

Subject(s) - linezolid , staphylococcus aureus , pneumonia , methicillin resistant staphylococcus aureus , in vivo , vancomycin , microbiology and biotechnology , medicine , immunology , biology , bacteria , genetics

Linezolid is recommended for treatment of pneumonia and other invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA). The premise underlying this recommendation is that linezolid inhibits in vivo production of potent staphylococcal exotoxins, including Panton-Valentine leukocidin (PVL) and α-hemolysin (Hla), although supporting evidence is lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research